In the past week, TOI stock has gone up by 19.60%, with a monthly decline of -39.58% and a quarterly plunge of -43.52%. The volatility ratio for the week is 17.85%, and the volatility levels for the last 30 days are 19.39% for Oncology Institute Inc The simple moving average for the past 20 days is -12.01% for TOI’s stock, with a -74.15% simple moving average for the past 200 days.
Is It Worth Investing in Oncology Institute Inc (NASDAQ: TOI) Right Now?
TOI has 36-month beta value of 0.44. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TOI is 36.71M, and currently, short sellers hold a 1.15% ratio of that float. The average trading volume of TOI on December 03, 2024 was 1.14M shares.
TOI) stock’s latest price update
Oncology Institute Inc (NASDAQ: TOI)’s stock price has increased by 16.53 compared to its previous closing price of 0.16. However, the company has seen a 19.60% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-21 that Proof that Digital Transformation and Smarter Supply Chains Can Massively Cut Costs Proof that Digital Transformation and Smarter Supply Chains Can Massively Cut Costs
Analysts’ Opinion of TOI
Many brokerage firms have already submitted their reports for TOI stocks, with Jefferies repeating the rating for TOI by listing it as a “Buy.” The predicted price for TOI in the upcoming period, according to Jefferies is $2.50 based on the research report published on February 26, 2024 of the current year 2024.
Guggenheim, on the other hand, stated in their research note that they expect to see TOI reach a price target of $7. The rating they have provided for TOI stocks is “Buy” according to the report published on September 14th, 2022.
Jefferies gave a rating of “Buy” to TOI, setting the target price at $10 in the report published on August 15th of the previous year.
TOI Trading at -34.11% from the 50-Day Moving Average
After a stumble in the market that brought TOI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.75% of loss for the given period.
Volatility was left at 19.39%, however, over the last 30 days, the volatility rate increased by 17.85%, as shares sank -34.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.55% lower at present.
During the last 5 trading sessions, TOI rose by +21.45%, which changed the moving average for the period of 200-days by -90.56% in comparison to the 20-day moving average, which settled at $0.2061. In addition, Oncology Institute Inc saw -91.12% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TOI starting from Hively Brad, who purchase 250,000 shares at the price of $0.17 back on Nov 26 ’24. After this action, Hively Brad now owns 616,753 shares of Oncology Institute Inc, valued at $42,500 using the latest closing price.
Hively Brad, the Director of Oncology Institute Inc, purchase 50,000 shares at $0.15 during a trade that took place back on Dec 02 ’24, which means that Hively Brad is holding 666,753 shares at $7,500 based on the most recent closing price.
Stock Fundamentals for TOI
Current profitability levels for the company are sitting at:
- -0.17 for the present operating margin
- 0.13 for the gross margin
The net margin for Oncology Institute Inc stands at -0.17. The total capital return value is set at -0.48. Equity return is now at value -131.66, with -28.92 for asset returns.
Based on Oncology Institute Inc (TOI), the company’s capital structure generated 0.86 points at debt to capital in total, while cash flow to debt ratio is standing at -0.38. The debt to equity ratio resting at 5.91. The interest coverage ratio of the stock is -7.68.
Currently, EBITDA for the company is -70.45 million with net debt to EBITDA at -1.19. When we switch over and look at the enterprise to sales, we see a ratio of 0.23. The receivables turnover for the company is 6.91for trailing twelve months and the total asset turnover is 2.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.49.
Conclusion
To put it simply, Oncology Institute Inc (TOI) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
